Mirum Pharmaceuticals, Inc. (MIRM) stock
Close on Nov 17, 2026Market cap $5.97BP/E –Yield –
Earnings
Mirum Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Mirum Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026after the close | $185.70M | +39.6% | -$0.87 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $176.20M | +37.9% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | $159.90M | +43.3% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $148.93M | +49.8% | -$0.47 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $133.00M | – | $0.05 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $127.80M | +64.1% | -$0.12 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | $111.60M | +61.3% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | $99.41M | +42.9% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | $77.88M | +107.7% | -$0.52 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $69.20M | – | -$0.54 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $69.55M | +149.2% | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $47.70M | +153.7% | -$0.57 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $37.50M | +114.3% | -$1.94 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023after the close | $27.91M | +800.2% | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022before the open | $18.80M | +276.0% | -$1.02 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $17.50M | – | -$0.84 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $12.90M | – | -$1.17 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 9, 2022after the close | $3.10M | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | $5.00M | – | -$1.55 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Mirum Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| net product sales | FY2026 | $715.00M – $720.00M | $630.00M – $650.00M | Raised | Nov 3, 2026 |
| net product sales guidance | FY2026 | $680.00M – $700.00M | $660.00M – $680.00M | Raised | Aug 5, 2026 |
Guidance vs results
The last range Mirum Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $500.00M – $510.00M | $521.33MΣ4Q | Above range |
| Q1 FY2022 | Revenue | $8.00M | $12.90M | Above range |
Guidance history
Every forecast Mirum Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | net product sales | FY2026 | $715.00M – $720.00M | Raised |
| Aug 5, 2026 | net product sales guidance | FY2026 | $680.00M – $700.00M | Raised |
| May 6, 2026 | net product sales | FY2026 | $660.00M – $680.00M | Raised |
| Feb 25, 2026 | global net product sales | FY2026 | $630.00M – $650.00M | New |
| Jan 12, 2026 | global net product sales | FY2026 | $630.00M – $650.00M | New |
| Nov 4, 2025 | revenue guidance | FY2025 | $500.00M – $510.00M | New |
| Aug 6, 2025 | revenue guidance | FY2025 | $490.00M – $510.00M | Raised |
| May 7, 2025 | revenue | FY2025 | $435.00M – $450.00M | Raised |
| Feb 26, 2025 | global net product sales | FY2025 | $420.00M – $435.00M | Reaffirmed |
| Jan 13, 2025 | global net product sales | FY2025 | $420.00M – $435.00M | New |
| Nov 12, 2024 | guidance | FY2024 | $330.00M – $335.00M | Raised |
| Aug 7, 2024 | global net product sales | FY2024 | $310.00M – $320.00M | Reaffirmed |
| May 8, 2024 | total revenue | FY2024 | $310.00M – $320.00M | Reaffirmed |
| Feb 28, 2024 | global net product sales | FY2024 | $310.00M – $320.00M | New |
| Aug 3, 2023 | US net product sales growth | FY2023 | +50% | Reaffirmed |
| Mar 8, 2023 | net product sales growth | FY2023 | +50% | New |
| Nov 9, 2022 | net product sales | FY2022 | $70.00M | New |
| Mar 9, 2022 | LIVMARLI net product sales | Q1 FY2022 | $8.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Mirum Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- Results
- Results
- Update
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
See a number that looks wrong?